+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Targeted Drug Delivery System Market - Global Forecast 2026-2032- Product Image
Targeted Drug Delivery System Market - Global Forecast 2026-2032- Product Image
Sale

Targeted Drug Delivery System Market - Global Forecast 2026-2032

  • Report

  • 187 Pages
  • July 2026
  • Region: Global
  • 360iResearch™
  • ID: 5336727
UP TO OFF until Dec 31st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Targeted Drug Delivery System Market is projected to reach USD 13.95 Billion in 2026. It is expected to continue growing at a CAGR of 7.26%, reaching USD 21.28 Billion by 2032.

Targeted drug delivery systems are reshaping pharmaceutical development by improving the precision with which therapeutic agents reach specific tissues, cells, or molecular pathways. These systems include nanoparticles, liposomes, antibody-drug conjugates, polymeric carriers, ligand-mediated platforms, implantable delivery devices, and stimuli-responsive formulations designed to enhance therapeutic efficacy while reducing systemic toxicity. Demand is being supported by the growing burden of cancer, autoimmune disorders, infectious diseases, neurological conditions, and chronic metabolic diseases, where conventional dosing often faces limitations related to bioavailability, off-target effects, and patient adherence. Regulatory agencies continue to encourage innovation in complex biologics, nanomedicines, and combination products through evolving guidance on quality, safety, pharmacokinetics, biodistribution, and long-term monitoring. As precision medicine expands, targeted drug delivery is increasingly connected to companion diagnostics, biomarker-led patient selection, controlled-release technologies, and personalized treatment pathways.

Transformative Shifts in the Targeted Drug Delivery Landscape

The targeted drug delivery system landscape is undergoing transformative shifts driven by advances in nanotechnology, biologics engineering, material science, and digital health integration. Oncology remains a leading application area due to the need to concentrate cytotoxic, immunomodulatory, or gene-based therapies at tumor sites while sparing healthy tissue. At the same time, mRNA and nucleic acid therapeutics have accelerated interest in lipid nanoparticles and other carrier systems capable of protecting fragile payloads and enabling intracellular delivery. The sector is also moving toward multifunctional platforms that combine targeting ligands, controlled release, imaging capability, and immune modulation in a single system. Manufacturing is evolving from laboratory-scale formulation toward scalable, reproducible, and quality-controlled production, with increasing attention to sterility, particle-size consistency, stability, and regulatory comparability. Sustainability and supply chain resilience are also becoming more important as specialized excipients, high-purity lipids, polymers, and biologic components require reliable sourcing and validated processing.

Cumulative Impact of Artificial Intelligence on Targeted Drug Delivery

Artificial intelligence is strengthening targeted drug delivery by accelerating carrier design, formulation optimization, payload selection, and patient stratification. Machine learning models can analyze physicochemical properties, tissue barriers, receptor expression, pharmacokinetic behavior, and toxicity signals to support rational design of nanoparticles, conjugates, and controlled-release systems. AI-enabled image analysis is improving interpretation of biodistribution, tumor penetration, organ accumulation, and treatment response in preclinical and clinical research. Predictive analytics also supports adaptive trial design, biomarker discovery, and identification of patient subgroups most likely to benefit from targeted therapeutics. In manufacturing, AI and advanced analytics can help monitor critical quality attributes such as particle size, encapsulation efficiency, release kinetics, and batch consistency. Despite these advantages, adoption requires validated datasets, explainable models, data governance, and alignment with regulatory expectations for software-assisted decision-making in drug development.

Key Regional Insights Across Targeted Drug Delivery Systems

Asia-Pacific is a major growth center for targeted drug delivery innovation due to expanding biopharmaceutical manufacturing, rising clinical trial activity, and significant public and private investment in oncology, vaccines, and advanced therapeutics across China, India, Japan, South Korea, Australia, and ASEAN economies. North America remains highly influential because of its mature biotechnology ecosystem, strong academic research networks, advanced clinical infrastructure, and established regulatory pathways for complex biologics, nanomedicines, and combination products. Latin America is advancing through improved access to specialty medicines, increasing oncology care capacity, and growing interest in local clinical research, particularly in Brazil and Mexico. Europe benefits from robust translational research, harmonized regulatory structures, high standards for pharmacovigilance, and strong capabilities in biologics, polymer science, and precision medicine. The Middle East is investing in advanced healthcare infrastructure, specialty hospitals, and national life sciences strategies, with increasing demand for innovative therapies in oncology and chronic disease management. Africa presents rising long-term relevance as healthcare systems expand access to essential medicines, cancer treatment, vaccines, and infectious disease programs, though targeted delivery adoption is shaped by affordability, cold-chain capacity, regulatory strengthening, and local manufacturing development.

Key Group Insights for Targeted Drug Delivery Adoption

ASEAN is gaining relevance in targeted drug delivery through expanding pharmaceutical production, growing clinical trial participation, and government efforts to strengthen healthcare access, although regulatory harmonization and advanced manufacturing capacity continue to develop unevenly across member states. The GCC is prioritizing high-quality healthcare infrastructure, oncology centers, digital health, and medical innovation, creating opportunities for advanced injectable, biologic, and precision therapy delivery platforms. The European Union supports targeted drug delivery through coordinated regulatory oversight, research funding, health technology assessment frameworks, and cross-border scientific collaboration, with emphasis on safety, quality, and equitable access. BRICS economies are important to global development because they combine large patient populations, increasing biopharmaceutical capabilities, expanding domestic innovation policies, and demand for cost-effective advanced therapies. G7 countries continue to set many scientific, regulatory, and reimbursement benchmarks for nanomedicine, biologics, gene-based therapeutics, and complex drug-device combinations. NATO member countries, many of which overlap with advanced pharmaceutical markets, also support biomedical preparedness, secure supply chains, and innovation relevant to controlled delivery, vaccines, and specialty therapeutics for civilian and defense health priorities.

Key Country Insights in Targeted Drug Delivery Systems

The United States leads in advanced therapeutic research, oncology innovation, clinical trial density, and regulatory experience with complex biologics, nanomedicines, antibody-drug conjugates, and gene delivery platforms. Canada contributes through strong academic medicine, biotechnology clusters, and public research support, while Mexico is improving its role in regional manufacturing and clinical access for specialty medicines. Brazil is Latin America’s largest healthcare and biopharmaceutical hub, supporting oncology research, vaccines, and local production initiatives. In Europe, the United Kingdom maintains strengths in translational medicine, genomics, and clinical research; Germany is prominent in pharmaceutical engineering, biologics, and advanced manufacturing; France supports oncology, immunology, and nanomedicine research; Italy and Spain contribute through hospital-based research networks and specialty care expansion; and Russia maintains scientific capabilities in biotechnology and vaccine platforms while facing access and collaboration constraints shaped by geopolitical conditions. China is rapidly advancing in biologics, oncology therapeutics, lipid nanoparticle research, and domestic innovation, supported by large-scale clinical development capacity. India is expanding in generic complex formulations, biosimilars, vaccines, and cost-efficient pharmaceutical manufacturing. Japan brings deep expertise in drug formulation, regenerative medicine, oncology, and regulatory pathways for advanced therapies. Australia is recognized for early-phase clinical research, biomedical science, and trial infrastructure, while South Korea has strong capabilities in biologics manufacturing, oncology research, and advanced healthcare technology adoption.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically validated targeting mechanisms, scalable manufacturing, and strong evidence generation to improve the success of targeted drug delivery programs. Early integration of biomarker strategy, companion diagnostics, and patient-selection criteria can improve trial efficiency and therapeutic relevance. Developers should strengthen formulation analytics, stability testing, release profiling, biodistribution assessment, and immunogenicity evaluation to meet regulatory expectations for complex systems. Partnerships across academic laboratories, contract development organizations, hospital networks, and digital analytics teams can accelerate translation from discovery to clinical application. Leaders should also invest in AI-enabled formulation development, continuous process monitoring, and quality-by-design approaches while ensuring transparent data governance. To improve access, organizations should plan for cold-chain requirements, local regulatory pathways, reimbursement evidence, and cost-effective manufacturing from the earliest development stages.

Research Methodology

This executive summary is developed using a structured secondary research approach based on verified public sources, regulatory guidance, peer-reviewed scientific literature, clinical trial registries, public health datasets, and recognized industry documentation related to targeted drug delivery systems. The methodology emphasizes evidence triangulation across therapeutic applications, delivery technologies, regional regulatory environments, manufacturing considerations, and healthcare adoption factors. Key themes are assessed through qualitative analysis of nanomedicine, biologics, antibody-drug conjugates, nucleic acid delivery, controlled-release platforms, and drug-device combination developments. Regional, group, and country insights are synthesized from publicly available healthcare infrastructure indicators, research activity, regulatory frameworks, clinical development trends, and pharmaceutical manufacturing capabilities. The analysis avoids unsupported projections and does not include market sizing, market share, or forecasting; instead, it focuses on data-backed structural drivers, technology shifts, policy factors, and adoption dynamics.

Conclusion

Targeted drug delivery systems are becoming central to the future of precision therapeutics by enabling more selective, efficient, and patient-centered treatment. Advances in nanoparticles, biologic conjugates, ligand-mediated delivery, controlled-release materials, and nucleic acid carriers are expanding the possibilities for treating cancer, inflammatory disease, infectious disease, neurological disorders, and other high-burden conditions. Artificial intelligence, biomarker science, and advanced manufacturing are further improving the design, validation, and scalability of these platforms. Regional adoption will depend on scientific capability, regulatory maturity, healthcare infrastructure, reimbursement readiness, and manufacturing resilience. Organizations that align clinical evidence, quality systems, digital tools, and access strategy will be best positioned to translate targeted drug delivery innovation into meaningful therapeutic impact.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Targeted Drug Delivery System Market, by Carrier Type
7.1. Introduction
7.2. Antibody Drug Conjugates
7.3. Dendrimers
7.4. Microspheres
7.5. Nanoparticles
7.5.1. Lipid Nanoparticles
7.5.2. Polymeric Nanoparticles
7.6. Liposomes
8. Targeted Drug Delivery System Market, by Targeting Mechanism
8.1. Introduction
8.2. Molecular Targeting
8.2.1. Antibody-Based
8.2.2. Ligand-Based
8.2.3. Nucleic Acid-Based
8.3. Physical / Device-Assisted Targeting
8.3.1. Implantable Device-Based
8.3.2. Topical Devices
9. Targeted Drug Delivery System Market, by Delivery Route
9.1. Introduction
9.2. Inhalation
9.2.1. Dry Powder Inhaler
9.2.2. Nebulizer
9.3. Intraocular
9.4. Intravenous
9.5. Injectable
9.6. Oral
9.7. Transdermal
10. Targeted Drug Delivery System Market, by Development Stage
10.1. Introduction
10.2. Preclinical
10.3. Phase I
10.4. Phase II
10.5. Phase III
11. Targeted Drug Delivery System Market, by Sales Channel
11.1. Introduction
11.2. Direct Tender
11.3. Hospital Pharmacy
11.4. Online Pharmacy
11.5. Retail Pharmacy
12. Targeted Drug Delivery System Market, by Application
12.1. Introduction
12.2. Autoimmune
12.3. Cardiovascular
12.4. Oncology
12.4.1. Breast Cancer
12.4.2. Colorectal Cancer
12.4.3. Lung Cancer
12.5. Orthopedic
12.6. Neurology
13. Targeted Drug Delivery System Market, by End User
13.1. Introduction
13.2. Pharmaceutical & Biotechnology Companies
13.3. Contract Research & Manufacturing Organizations
13.4. Academic & Research Institutes
13.5. Hospitals & Specialty Clinics
14. Targeted Drug Delivery System Market, by Region
14.1. Asia-Pacific
14.2. North America
14.3. Europe
14.4. Latin America
14.5. Africa
14.6. Middle East
15. Targeted Drug Delivery System Market, by Group
15.1. NATO
15.2. G7
15.3. BRICS
15.4. European Union
15.5. ASEAN
15.6. GCC
16. Targeted Drug Delivery System Market, by Country
16.1. United States
16.2. China
16.3. Canada
16.4. Japan
16.5. Germany
16.6. India
16.7. Brazil
16.8. Mexico
16.9. United Kingdom
16.10. France
16.11. Australia
16.12. Italy
16.13. South Korea
16.14. Russia
16.15. Spain
17. Competitive Landscape
17.1. Market Share Analysis, 2025
17.2. FPNV Positioning Matrix, 2025
17.3. Market Concentration Analysis, 2025
17.3.1. Concentration Ratio (CR)
17.3.2. Herfindahl Hirschman Index (HHI)
17.4. Recent Developments & Impact Analysis, 2025
17.5. Product Portfolio Analysis, 2025
17.6. Benchmarking Analysis, 2025
18. Company Profiles
18.1. Johnson & Johnson Service, Inc.
18.2. F. Hoffmann-La Roche Ltd
18.3. Pfizer Inc.
18.4. Merck KGaA
18.5. AstraZeneca Plc
18.6. Novartis AG
18.7. Abbott Laboratories
18.8. Thermo Fisher Scientific Inc.
18.9. AptarGroup, Inc.
18.10. Medtronic PLC
18.11. Boston Scientific Corporation
18.12. Biogen Inc.
18.13. Acuitas Therapeutics, Inc.
18.14. Alnylam Pharmaceuticals, Inc.
18.15. Cospheric LLC
18.16. DelSiTech Ltd.
18.17. Enable Injections, Inc.
18.18. GSK Plc.
18.19. Insulet Corporation
18.20. Merit Medical Systems, Inc.
18.21. Pacira BioSciences, Inc.
18.22. Polysciences Inc.
18.23. Sanofi S.A.
18.24. SHL Medical AG
18.25. Terumo Corporation
List of Figures
FIGURE 1. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 6. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY CARRIER TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY CARRIER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TARGETING MECHANISM, 2025 VS 2032 (%)
FIGURE 9. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TARGETING MECHANISM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2025 VS 2032 (%)
FIGURE 11. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DEVELOPMENT STAGE, 2025 VS 2032 (%)
FIGURE 13. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DEVELOPMENT STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2025 VS 2032 (%)
FIGURE 15. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 19. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 21. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 23. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 25. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 27. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY CARRIER TYPE, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL ANTIBODY DRUG CONJUGATES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL ANTIBODY DRUG CONJUGATES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL ANTIBODY DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL DENDRIMERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL DENDRIMERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL DENDRIMERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL MICROSPHERES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL MICROSPHERES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL MICROSPHERES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL NANOPARTICLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL NANOPARTICLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL NANOPARTICLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL LIPID NANOPARTICLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL LIPID NANOPARTICLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL LIPID NANOPARTICLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL POLYMERIC NANOPARTICLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL POLYMERIC NANOPARTICLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL POLYMERIC NANOPARTICLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL LIPOSOMES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL LIPOSOMES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL LIPOSOMES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TARGETING MECHANISM, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL MOLECULAR TARGETING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL MOLECULAR TARGETING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL MOLECULAR TARGETING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL ANTIBODY-BASED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL ANTIBODY-BASED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL ANTIBODY-BASED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL LIGAND-BASED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL LIGAND-BASED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL LIGAND-BASED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL NUCLEIC ACID-BASED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL NUCLEIC ACID-BASED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL NUCLEIC ACID-BASED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL PHYSICAL / DEVICE-ASSISTED TARGETING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL PHYSICAL / DEVICE-ASSISTED TARGETING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL PHYSICAL / DEVICE-ASSISTED TARGETING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL IMPLANTABLE DEVICE-BASED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL IMPLANTABLE DEVICE-BASED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL IMPLANTABLE DEVICE-BASED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL TOPICAL DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL TOPICAL DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL TOPICAL DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL INHALATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL INHALATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL INHALATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL DRY POWDER INHALER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL DRY POWDER INHALER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL DRY POWDER INHALER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL NEBULIZER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL NEBULIZER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL NEBULIZER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL INTRAOCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL INTRAOCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL INTRAOCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL TRANSDERMAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL TRANSDERMAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL TRANSDERMAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL PRECLINICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL PRECLINICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL PRECLINICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL PHASE I MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL PHASE I MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL PHASE I MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL PHASE II MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL PHASE II MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL PHASE II MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL PHASE III MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL PHASE III MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL PHASE III MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL DIRECT TENDER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL DIRECT TENDER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL DIRECT TENDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL AUTOIMMUNE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL AUTOIMMUNE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL AUTOIMMUNE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL CARDIOVASCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL CARDIOVASCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL CARDIOVASCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL BREAST CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL BREAST CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL BREAST CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL COLORECTAL CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL COLORECTAL CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL COLORECTAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 114. GLOBAL LUNG CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 115. GLOBAL LUNG CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 116. GLOBAL LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 117. GLOBAL ORTHOPEDIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 118. GLOBAL ORTHOPEDIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 119. GLOBAL ORTHOPEDIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 120. GLOBAL NEUROLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 121. GLOBAL NEUROLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 122. GLOBAL NEUROLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 123. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 124. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 125. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 126. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 127. GLOBAL CONTRACT RESEARCH & MANUFACTURING ORGANIZATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 128. GLOBAL CONTRACT RESEARCH & MANUFACTURING ORGANIZATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 129. GLOBAL CONTRACT RESEARCH & MANUFACTURING ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 130. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 131. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 132. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 133. GLOBAL HOSPITALS & SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 134. GLOBAL HOSPITALS & SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 135. GLOBAL HOSPITALS & SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 136. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 137. ASIA-PACIFIC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 138. ASIA-PACIFIC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY CARRIER TYPE, 2018-2032 (USD MILLION)
TABLE 139. ASIA-PACIFIC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY NANOPARTICLES, 2018-2032 (USD MILLION)
TABLE 140. ASIA-PACIFIC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TARGETING MECHANISM, 2018-2032 (USD MILLION)
TABLE 141. ASIA-PACIFIC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY MOLECULAR TARGETING, 2018-2032 (USD MILLION)
TABLE 142. ASIA-PACIFIC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY PHYSICAL / DEVICE-ASSISTED TARGETING, 2018-2032 (USD MILLION)
TABLE 143. ASIA-PACIFIC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
TABLE 144. ASIA-PACIFIC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
TABLE 145. ASIA-PACIFIC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 146. ASIA-PACIFIC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
TABLE 147. ASIA-PACIFIC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 148. ASIA-PACIFIC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 149. ASIA-PACIFIC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 150. NORTH AMERICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 151. NORTH AMERICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY CARRIER TYPE, 2018-2032 (USD MILLION)
TABLE 152. NORTH AMERICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY NANOPARTICLES, 2018-2032 (USD MILLION)
TABLE 153. NORTH AMERICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TARGETING MECHANISM, 2018-2032 (USD MILLION)
TABLE 154. NORTH AMERICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY MOLECULAR TARGETING, 2018-2032 (USD MILLION)
TABLE 155. NORTH AMERICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY PHYSICAL / DEVICE-ASSISTED TARGETING, 2018-2032 (USD MILLION)
TABLE 156. NORTH AMERICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
TABLE 157. NORTH AMERICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
TABLE 158. NORTH AMERICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 159. NORTH AMERICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
TABLE 160. NORTH AMERICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 161. NORTH AMERICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 162. NORTH AMERICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 163. EUROPE TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 164. EUROPE TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY CARRIER TYPE, 2018-2032 (USD MILLION)
TABLE 165. EUROPE TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY NANOPARTICLES, 2018-2032 (USD MILLION)
TABLE 166. EUROPE TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TARGETING MECHANISM, 2018-2032 (USD MILLION)
TABLE 167. EUROPE TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY MOLECULAR TARGETING, 2018-2032 (USD MILLION)
TABLE 168. EUROPE TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY PHYSICAL / DEVICE-ASSISTED TARGETING, 2018-2032 (USD MILLION)
TABLE 169. EUROPE TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
TABLE 170. EUROPE TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
TABLE 171. EUROPE TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 172. EUROPE TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
TABLE 173. EUROPE TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 174. EUROPE TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 175. EUROPE TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 176. LATIN AMERICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 177. LATIN AMERICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY CARRIER TYPE, 2018-2032 (USD MILLION)
TABLE 178. LATIN AMERICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY NANOPARTICLES, 2018-2032 (USD MILLION)
TABLE 179. LATIN AMERICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TARGETING MECHANISM, 2018-2032 (USD MILLION)
TABLE 180. LATIN AMERICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY MOLECULAR TARGETING, 2018-2032 (USD MILLION)
TABLE 181. LATIN AMERICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY PHYSICAL / DEVICE-ASSISTED TARGETING, 2018-2032 (USD MILLION)
TABLE 182. LATIN AMERICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
TABLE 183. LATIN AMERICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
TABLE 184. LATIN AMERICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 185. LATIN AMERICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
TABLE 186. LATIN AMERICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 187. LATIN AMERICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 188. LATIN AMERICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 189. AFRICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 190. AFRICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY CARRIER TYPE, 2018-2032 (USD MILLION)
TABLE 191. AFRICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY NANOPARTICLES, 2018-2032 (USD MILLION)
TABLE 192. AFRICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TARGETING MECHANISM, 2018-2032 (USD MILLION)
TABLE 193. AFRICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY MOLECULAR TARGETING, 2018-2032 (USD MILLION)
TABLE 194. AFRICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY PHYSICAL / DEVICE-ASSISTED TARGETING, 2018-2032 (USD MILLION)
TABLE 195. AFRICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
TABLE 196. AFRICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
TABLE 197. AFRICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 198. AFRICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
TABLE 199. AFRICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 200. AFRICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 201. AFRICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 202. MIDDLE EAST TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 203. MIDDLE EAST TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY CARRIER TYPE, 2018-2032 (USD MILLION)
TABLE 204. MIDDLE EAST TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY NANOPARTICLES, 2018-2032 (USD MILLION)
TABLE 205. MIDDLE EAST TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TARGETING MECHANISM, 2018-2032 (USD MILLION)
TABLE 206. MIDDLE EAST TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY MOLECULAR TARGETING, 2018-2032 (USD MILLION)
TABLE 207. MIDDLE EAST TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY PHYSICAL / DEVICE-ASSISTED TARGETING, 2018-2032 (USD MILLION)
TABLE 208. MIDDLE EAST TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
TABLE 209. MIDDLE EAST TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
TABLE 210. MIDDLE EAST TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 211. MIDDLE EAST TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
TABLE 212. MIDDLE EAST TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 213. MIDDLE EAST TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 214. MIDDLE EAST TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 215. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 216. NATO TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 217. NATO TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY CARRIER TYPE, 2018-2032 (USD MILLION)
TABLE 218. NATO TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY NANOPARTICLES, 2018-2032 (USD MILLION)
TABLE 219. NATO TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TARGETING MECHANISM, 2018-2032 (USD MILLION)
TABLE 220. NATO TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY MOLECULAR TARGETING, 2018-2032 (USD MILLION)
TABLE 221. NATO TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY PHYSICAL / DEVICE-ASSISTED TARGETING, 2018-2032 (USD MILLION)
TABLE 222. NATO TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
TABLE 223. NATO TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
TABLE 224. NATO TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 225. NATO TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
TABLE 226. NATO TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 227. NATO TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 228. NATO TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 229. G7 TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 230. G7 TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY CARRIER TYPE, 2018-2032 (USD MILLION)
TABLE 231. G7 TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY NANOPARTICLES, 2018-2032 (USD MILLION)
TABLE 232. G7 TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TARGETING MECHANISM, 2018-2032 (USD MILLION)
TABLE 233. G7 TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY MOLECULAR TARGETING, 2018-2032 (USD MILLION)
TABLE 234. G7 TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY PHYSICAL / DEVICE-ASSISTED TARGETING, 2018-2032 (USD MILLION)
TABLE 235. G7 TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
TABLE 236. G7 TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
TABLE 237. G7 TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 238. G7 TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
TABLE 239. G7 TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 240. G7 TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 241. G7 TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 242. BRICS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 243. BRICS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY CARRIER TYPE, 2018-2032 (USD MILLION)
TABLE 244. BRICS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY NANOPARTICLES, 2018-2032 (USD MILLION)
TABLE 245. BRICS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TARGETING MECHANISM, 2018-2032 (USD MILLION)
TABLE 246. BRICS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY MOLECULAR TARGETING, 2018-2032 (USD MILLION)
TABLE 247. BRICS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY PHYSICAL / DEVICE-ASSISTED TARGETING, 2018-2032 (USD MILLION)
TABLE 248. BRICS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
TABLE 249. BRICS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
TABLE 250. BRICS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 251. BRICS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
TABLE 252. BRICS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 253. BRICS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 254. BRICS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 255. EUROPEAN UNION TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 256. EUROPEAN UNION TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY CARRIER TYPE, 2018-2032 (USD MILLION)
TABLE 257. EUROPEAN UNION TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY NANOPARTICLES, 2018-2032 (USD MILLION)
TABLE 258. EUROPEAN UNION TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TARGETING MECHANISM, 2018-2032 (USD MILLION)
TABLE 259. EUROPEAN UNION TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY MOLECULAR TARGETING, 2018-2032 (USD MILLION)
TABLE 260. EUROPEAN UNION TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY PHYSICAL / DEVICE-ASSISTED TARGETING, 2018-2032 (USD MILLION)
TABLE 261. EUROPEAN UNION TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
TABLE 262. EUROPEAN UNION TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
TABLE 263. EUROPEAN UNION TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 264. EUROPEAN UNION TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
TABLE 265. EUROPEAN UNION TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 266. EUROPEAN UNION TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 267. EUROPEAN UNION TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 268. ASEAN TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 269. ASEAN TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY CARRIER TYPE, 2018-2032 (USD MILLION)
TABLE 270. ASEAN TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY NANOPARTICLES, 2018-2032 (USD MILLION)
TABLE 271. ASEAN TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TARGETING MECHANISM, 2018-2032 (USD MILLION)
TABLE 272. ASEAN TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY MOLECULAR TARGETING, 2018-2032 (USD MILLION)
TABLE 273. ASEAN TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY PHYSICAL / DEVICE-ASSISTED TARGETING, 2018-2032 (USD MILLION)
TABLE 274. ASEAN TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
TABLE 275. ASEAN TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
TABLE 276. ASEAN TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 277. ASEAN TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
TABLE 278. ASEAN TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 279. ASEAN TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 280. ASEAN TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 281. GCC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 282. GCC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY CARRIER TYPE, 2018-2032 (USD MILLION)
TABLE 283. GCC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY NANOPARTICLES, 2018-2032 (USD MILLION)
TABLE 284. GCC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TARGETING MECHANISM, 2018-2032 (USD MILLION)
TABLE 285. GCC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY MOLECULAR TARGETING, 2018-2032 (USD MILLION)
TABLE 286. GCC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY PHYSICAL / DEVICE-ASSISTED TARGETING, 2018-2032 (USD MILLION)
TABLE 287. GCC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
TABLE 288. GCC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
TABLE 289. GCC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 290. GCC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
TABLE 291. GCC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 292. GCC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 293. GCC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 294. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 295. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 296. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY CARRIER TYPE, 2018-2032 (USD MILLION)
TABLE 297. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY NANOPARTICLES, 2018-2032 (USD MILLION)
TABLE 298. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TARGETING MECHANISM, 2018-2032 (USD MILLION)
TABLE 299. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY MOLECULAR TARGETING, 2018-2032 (USD MILLION)
TABLE 300. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY PHYSICAL / DEVICE-ASSISTED TARGETING, 2018-2032 (USD MILLION)
TABLE 301. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
TABLE 302. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
TABLE 303. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 304. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
TABLE 305. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 306. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 307. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 308. CHINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 309. CHINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY CARRIER TYPE, 2018-2032 (USD MILLION)
TABLE 310. CHINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY NANOPARTICLES, 2018-2032 (USD MILLION)
TABLE 311. CHINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TARGETING MECHANISM, 2018-2032 (USD MILLION)
TABLE 312. CHINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY MOLECULAR TARGETING, 2018-2032 (USD MILLION)
TABLE 313. CHINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY PHYSICAL / DEVICE-ASSISTED TARGETING, 2018-2032 (USD MILLION)
TABLE 314. CHINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
TABLE 315. CHINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
TABLE 316. CHINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 317. CHINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
TABLE 318. CHINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 319. CHINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 320. CHINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 321. CANADA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 322. CANADA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY CARRIER TYPE, 2018-2032 (USD MILLION)
TABLE 323. CANADA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY NANOPARTICLES, 2018-2032 (USD MILLION)
TABLE 324. CANADA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TARGETING MECHANISM, 2018-2032 (USD MILLION)
TABLE 325. CANADA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY MOLECULAR TARGETING, 2018-2032 (USD MILLION)
TABLE 326. CANADA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY PHYSICAL / DEVICE-ASSISTED TARGETING, 2018-2032 (USD MILLION)
TABLE 327. CANADA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
TABLE 328. CANADA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
TABLE 329. CANADA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 330. CANADA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
TABLE 331. CANADA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 332. CANADA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 333. CANADA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 334. JAPAN TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 335. JAPAN TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY CARRIER TYPE, 2018-2032 (USD MILLION)
TABLE 336. JAPAN TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY NANOPARTICLES, 2018-2032 (USD MILLION)
TABLE 337. JAPAN TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TARGETING MECHANISM, 2018-2032 (USD MILLION)
TABLE 338. JAPAN TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY MOLECULAR TARGETING, 2018-2032 (USD MILLION)
TABLE 339. JAPAN TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY PHYSICAL / DEVICE-ASSISTED TA

Companies Mentioned

  • Johnson & Johnson Service, Inc.
  • F. Hoffmann-La Roche Ltd
  • Pfizer Inc.
  • Merck KGaA
  • AstraZeneca Plc
  • Novartis AG
  • Abbott Laboratories
  • Thermo Fisher Scientific Inc.
  • AptarGroup, Inc.
  • Medtronic PLC
  • Boston Scientific Corporation
  • Biogen Inc.
  • Acuitas Therapeutics, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Cospheric LLC
  • DelSiTech Ltd.
  • Enable Injections, Inc.
  • GSK Plc.
  • Insulet Corporation
  • Merit Medical Systems, Inc.
  • Pacira BioSciences, Inc.
  • Polysciences Inc.
  • Sanofi S.A.
  • SHL Medical AG
  • Terumo Corporation

Table Information

Report AttributeDetails
No. of Pages187
PublishedJuly 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 13.95 Billion
Forecasted Market Value ( USD ) by 2032 $ 21.28 Billion
Compound Annual Growth Rate7.2%
Regions CoveredGlobal
No. of Companies Mentioned25

Related Topics

Related Reports

Novel Drug Delivery Systems Market - Global Forecast 2026-2032 - Product Image

Novel Drug Delivery Systems Market - Global Forecast 2026-2032

  • Report
  • 193 Pages
  • Global
From
Drug Delivery Systems Market - Global Forecast 2026-2032 - Product Image

Drug Delivery Systems Market - Global Forecast 2026-2032

  • Report
  • 188 Pages
  • Global
From
Advanced Drug Delivery Systems - Global Strategic Business Report - Product Image

Advanced Drug Delivery Systems - Global Strategic Business Report

  • Report
  • 283 Pages
  • Global
From
Buccal Drug Delivery Systems - Global Strategic Business Report - Product Image

Buccal Drug Delivery Systems - Global Strategic Business Report

  • Report
  • 368 Pages
  • Global
From
Advanced Drug Delivery Systems Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

Advanced Drug Delivery Systems Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From

About the Market

Targeted Drug Delivery System (TDDS) is a specialized area within the broader pharmacological field of Drug Delivery. TDDS aims to direct medication to specific cells, tissues, or organs, thereby increasing the concentration of the drug at the intended site of action while minimizing its presence in the rest of the body. This method potentially reduces side effects and enhances treatment efficacy. The market for these systems encompasses a wide range of technologies and platforms, such as nanoparticles, liposomes, and biodegradable polymers designed to release pharmaceutical compounds in a controlled manner. The field has been propelled by advances in biotechnology, nanotechnology, and molecular biology, which have contributed to the development of novel targeted drug delivery mechanisms. These include antibodies, receptor-mediated delivery systems, and gene-delivery vectors. TDDS is used in addressing various medical conditions, with cancer therapy being a particularly active area due to the need for precise drug delivery to tumor cells. Several companies specialize in the research and development of Targeted Drug Delivery Systems, contributing to the maturation of this market. Some notable players in the field include Alkermes, BIND Therapeutics, DEPArray Technology, Genentech, Immunomedics, Inc., and Kite Pharma. These companies have a diverse product portfolio of targeted delivery technologies and are engaged in the development of innovative treatments for a wide range of diseases, striving to improve therapeutic outcomes and patient quality of life. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.